You are here: Industry Insights > Eli Lilly

News List

EFSD, JDRF and Lilly Extend Collaboration Supporting Type 1 Diabetes Research biospace
March 09, 2018
The European Foundation for the Study of Diabetes (EFSD), JDRF and Eli Lilly and Company (NYSE: LLY) have agreed to extend their collaboration for the European Programme in Type 1 Diabetes Research through 2020
Next Generation Biologics, Janssen's Tremfya, Eli Lilly's Taltz, and Novartis' Cosentyx, Raising the biospace
March 09, 2018
The past three years have brought with them a flurry of branded biologic approvals in dermatology, including four biologics for psoriasis alone
Lilly Exploring Strategic Alternatives for Animal Health Biz biospace
February 02, 2018
Eli Lilly and Company (NYSE: LLY) today announced financial results for the fourth quarter and full year of 2017.
Lilly and KeyBioscience collaborate to develop potential type 2 diabetes treatment pharmaceutical-technology
June 13, 2017
US-based Eli Lilly and Company has collaborated with Nordic Bioscience subsidiary KeyBioscience to develop Dual Amylin Calcitonin Receptor Agonists (DACRAs), a potential new class of treatments for patients with metabolic disorders such as type 2 diabetes